SARS-CoV-2 (COVID-19) Nucleocapsid Matched Pair

Contact us
ProSci
Product Code: PSI-MPN-0003
Product Group: Antibody Pairs
Supplier: ProSci
CodeSizePrice
PSI-MPN-0003-1Set1Set£859.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Antibody Clonality: Mixed
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Storage:
Store at -20˚C, stable for up to one year.

Documents

Further Information

Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019?20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).
Background References:
  • Zhu et al. N Engl J Med. 2020 Feb 20;382(8):727-733.
  • Kiyotani et al. J Hum Genet. 2020 Jul;65(7):569-575.
  • Chang et al. J Biomed Sci. 2006 Jan;13(1):59-72.
  • Cui et al. J Virol. 2015 Sep;89(17):9029-43.
Concentration:
batch dependent
Physical State:
Liquid
Set Contents:
Capture: SARS-CoV-2 (COVID-19) Nucleocapsid Antibody [3866], Cat. No. 35-720 (100 μg)

Detection: SARS-CoV-2 (COVID-19) Nucleocapsid Antibody, Cat. No. 9103 (100 μg)
User Note:
Optimal dilutions for each application to be determined by the researcher.

References

  1. Zhu et al. N Engl J Med. 2020 Feb 20;382(8):727-733.
  2. Kiyotani et al. J Hum Genet. 2020 Jul;65(7):569-575.
  3. Chang et al. J Biomed Sci. 2006 Jan;13(1):59-72.
  4. Cui et al. J Virol. 2015 Sep;89(17):9029-43.